Healthcare and Life Science
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical trial o...
New therapy that targets and destroys tau tangles is a promising future Alzheimer’s disease treatment
Medical Research Council media release.
Cambridge Enterprise appoints new Chief Executive
Dr Jim Glasheen has been appointed as Chief Executive of Cambridge Enterprise, the innovation arm of the University of Cambridge. Dr Glasheen will assume his post later in 2024. ...
New state-of-the-art radiotherapy equipment benefiting patients in the East
Cancer patients undergoing treatment at Norfolk and Norwich University Hospital’s NHS Foundation Trust (NNUH) and Cambridge University Hospitals NHS Foundation Trust (CUH) are benefiting from a new type of radiotherapy which reduces treatment time whilst increasing accuracy and patient ...
Breast and ovarian cancer newly linked to thousands of gene variants
Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer, paving the way for better risk assessment and more personalised care. ...
Significant progress made in meeting demand for lab and office space
A joint news release on behalf of Cambridge City Council and South Cambridgeshire District Council and Greater Cambridge Shared Planning. ...
Mission Street and BGO get go-ahead for 23-acre central Cambridge science district
CAMBRIDGE, UK - In a significant step forward for the UK’s aspirations to be a ‘science superpower’, specialist investor, developer and operator for the science and innovation sector Mission Street and BGO, a leading global real estate investment manager, received planning consent to de...
Nxera Pharma receives approval of QUVIVIQ (daridorexant) in Japan for the treatment of insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Ja...
Have a heart – learn CPR, says MP
In advance of World Heart Day, Daniel Zeichner, Member of Parliament for Cambridge, tried out RevivR, a new CPR training tool, at a British Heart Foundation (BHF) shop in Cambridge on Friday 20 September to highlight the charity's vital work in combating heart and circulatory diseases. ...
Hospital prosthetics service moves to high-tech new home
An Addenbrooke’s service that offers vital support for amputees and others officially opened on the 23rd Sept at a high-tech new home after nearly quarter of a century at the hospital. ...